Acadia Healthcare Company Inc.

---

source: coverage-next-full ticker: ACAD company: Acadia Healthcare Company, Inc. step: 01 title: Business Overview & Model created: 2026-05-27

Step 01 — Business Overview: Acadia Healthcare Company, Inc. (ACAD)

1. Business Description

Acadia Healthcare Company, Inc. (NASDAQ: ACAD; SEC: ACHC) is the largest publicly traded pure-play behavioral health company in the United States. The company operates a network of 277 behavioral healthcare facilities across 40 states and Puerto Rico, providing treatment for psychiatric disorders, substance use disorders (SUDs), and co-occurring conditions. [S1]

The company's mission centers on providing high-acuity, complex-needs behavioral health care to patients who lack adequate access to quality mental health and addiction treatment services. Acadia differentiates through scale, geographic density, continuum-of-care offerings, and its network of comprehensive treatment centers (CTCs) for opioid use disorder (OUD). [S2]

2. Value-Chain Layer Map

PAYER LAYER (Medicaid 57.7% / Commercial 24.6% / Medicare 14.3% / Other 3.4%)
       ↓ Reimbursement flows
ACADIA HEALTHCARE (Operator Layer)
  ├── Facility acquisition / de novo development / joint ventures
  ├── Facility operations management (staffing, compliance, clinical)
  ├── Clinical programs (inpatient psychiatry, residential, MAT, PHP/IOP)
  └── Billing / revenue cycle management
       ↓ Services delivered
PATIENT LAYER (82,000+ patients served daily)
  ├── Acute psychiatric episodes (AIP facilities)
  ├── Residential treatment (longer-term)
  ├── Medication-assisted treatment (CTCs — opioids)
  └── Outpatient / PHP / IOP (step-down care)

3. Business Segments

Acadia does not formally report disaggregated segment revenue by service line in its XBRL. Based on 10-K and press release disclosures: [S1][S2]

Service Line	Description	Estimated Revenue %
Acute Inpatient Psychiatric (AIP)	24/7 inpatient psychiatric hospital care	~55–60%
Residential Treatment	Longer-term residential programs (dual diagnosis, eating disorders, adolescent)	~15–20%
Comprehensive Treatment Centers (CTC)	Outpatient medication-assisted treatment for OUD (Suboxone/methadone)	~15–20%
Outpatient (PHP/IOP/Outpatient)	Partial hospitalization, intensive outpatient, standard outpatient	~5–10%

Q1 2026: Acute inpatient psychiatric facility revenue = $470.7M (+14% YoY), illustrating the inpatient segment's dominant position. [S3]

4. Revenue Model

Core Revenue Equation: Revenue = (Patient Days) × (Revenue Per Patient Day) × (Facility Count)

• Patient Days: Volume metric; driven by facility capacity, occupancy rates, and payor referral flow
• Revenue Per Patient Day (RPD): Pricing metric; driven by payor mix, rate negotiations, and acuity of care
• Facility Count: Capacity metric; driven by de novo development, acquisitions, and closures

Q1 2026 same-facility revenue growth: +7.3% (1.6% patient days + 5.6% RPD) [S3] — demonstrates that the company currently grows primarily through pricing, not volume.

5. Payer Mix and Revenue Architecture [S2]

Payer	FY2025 Revenue %
Medicaid	57.7%
Commercial	24.6%
Medicare	14.3%
Other (self-pay, govt)	3.4%

Medicaid dependency is the defining risk/characteristic of the business model. Medicaid rates are set by state programs; any state budget constraint can trigger rate cuts with direct margin impact. The company's 57.7% Medicaid concentration makes it highly sensitive to Medicaid policy.

6. Geographic Footprint

• States operated: 40 + Puerto Rico (Dec 2025) [S1]
• Facilities: 277 behavioral healthcare facilities [S1]
• Beds: 12,500+ [S1]
• CTC locations: 174 across 33 states [S2]
• Largest concentration: Southeast and Midwest, with presence in every major U.S. region

7. Growth Pathways (Five Strategic Vectors)

Per company disclosures, Acadia pursues five growth pathways: [S2]

1. Expansions of existing facilities (add beds/programs at existing sites)
2. Joint venture (JV) partnerships with health systems (shared ownership of new facilities)
3. De novo development (build new greenfield facilities; capital-intensive; 2-4 year startup losses)
4. Acquisitions (M&A of existing behavioral health operators)
5. Continuum expansion (adding service lines at existing facilities)

Current strategic posture (2025-2026): The company is pivoting away from aggressive de novo/acquisition growth toward organic optimization, cash flow generation, and debt reduction under activist/board pressure.

8. Recent Strategic Pivot

In September 2025, under activist and board pressure, Acadia announced: [S2][S4]

• CapEx reduction of ≥$300M in 2026 (from $572M in 2025 to $255-280M guided for 2026)
• Closure of 5 underperforming facilities
• Layoff of ~400 employees
• Pause on several growth projects
• Shift focus to FCF generation and same-facility performance improvement

This represents a significant strategic inflection from the growth-at-any-cost posture of 2022-2024.

Source Index

ID	Source
S1	SEC 10-K FY2025 (filed 2026-02-27): https://www.sec.gov/Archives/edgar/data/1520697
S2	Company 8-K FY2025 press release / Acadia IR: https://acadiahealthcare.gcs-web.com
S3	SEC 10-Q Q1 2026 (filed 2026-04-30): https://www.sec.gov/Archives/edgar/data/0001520697/000119312526192508
S4	Web search: Acadia Healthcare strategic pivot Oct 2025 (bhbusiness.com)

---

source: coverage-next-full ticker: ACAD company: Acadia Healthcare Company, Inc. step: 04 title: Financial Quality & Adversarial Research Sweep created: 2026-05-27

Step 04 — Financial Quality & Adversarial Research Sweep: ACAD

1. Statement Quality Adjustments

Income Statement Adjustments

Acadia's GAAP net income is distorted by several significant non-recurring or non-cash items. The following adjustments normalize the picture: [S1][S2]

Item	FY2024	FY2025	Classification
GAAP Net Income	$255.6M	($1,102.8M)	—
(+) Goodwill Impairment	$0	$996.2M	Non-cash, Non-recurring
(+) Securities Settlement	~$0	~$179M	Cash but non-recurring
(+) Legal investigation charges	~$135M	~$135M	Cash; elevated vs. steady-state
(+) D&A	$149.6M	$189.2M	Non-cash
(+) SBC	$37.1M	$31.7M	Non-cash
(+) Other adjustments (est.)	~$5M	~$5M	Various
≈ Adjusted EBITDA	~$572M	$608.9M	Clean operational metric

Judgment [J]: FY2025 GAAP loss of $1.1B is primarily non-cash (goodwill impairment) and event-driven (securities settlement). The underlying business generated ~$609M Adj. EBITDA — roughly flat-to-growing from FY2024. The key question is whether legal charges normalize meaningfully below $135M/yr as investigations resolve.

Cash Flow Adjustments

Operating cash flow is understated relative to true operating performance due to large cash legal payments: [S1]

Item	FY2024	FY2025
Reported OCF	$129.7M	$131.9M
(+) Cash legal payments (est.)	~$135M	~$135M
= Adjusted OCF	~$265M	~$267M

Note: Even adjusted, OCF is well below Adj. EBITDA (~$609M) due to working capital expansion (A/R growing as revenue scales), interest payments, and taxes.

Balance Sheet Quality

Goodwill: $1,296M (post-impairment) vs. $2,265M at FY2024 — the $996M write-down reflects management's acknowledgment that prior acquisition/de novo values were overstated. [S1]

Goodwill/Total Assets ratio: 23.5% (FY2025) — significant but manageable. Intangibles represent the cost of the company's growth-by-acquisition history.

Accounts Receivable: $440.6M — DSO ~49 days — normal for behavioral health where Medicaid/Medicare pay in 30-45 days but commercial claims can take longer. Allowance for doubtful accounts should be reviewed. [S1]

2. Adversarial Research Sweep

Short-Seller and Investigative Reports

No specific short-seller report identifying ACAD/ACHC as a primary target found in web research as of 2026-05-27. However, the DOJ/SEC investigation itself effectively serves as the "bear case" investigation:

Regulatory/Legal Actions [S3][S4]

Timeline of Legal/Regulatory Actions:

Date	Action	Amount	Status
2014-2017	Alleged Medicare/Medicaid/TRICARE billing fraud (unnecessary inpatient BH services)	—	Underlying period
2017	OIG/DOJ investigation commenced	—	Triggered investigation
Sep 2024	Civil settlement of OIG/DOJ whistleblower case	$19.85M	Resolved (no admission)
2023-2024	Securities class action lawsuit	—	Ongoing
Nov 2025	Securities class action settlement accrued	$179M	Pending finalization
2025	DOJ Criminal Division investigation ongoing	Unknown	Active
2025	SEC investigation ongoing	Unknown	Active
May 2026	Jury verdict: $105M damages to Acadia entity	Unknown context	Recent

Assessment: The DOJ Criminal Division investigation is the dominant tail risk. Criminal behavioral health fraud prosecutions have resulted in settlements of $500M-$2B+ for large operators. If charges are brought, the company could face:

• Criminal fines
• Corporate integrity agreement (CIA) requiring costly compliance programs
• Potential exclusion from Medicare/Medicaid (extreme scenario — existential)

Probability assessment [J]: Medicare/Medicaid exclusion is very low probability given the company's scale (would harm patients); a CIA + civil settlement is more likely. Settlement magnitude is uncertain but $200-500M range is plausible given the scope of the investigation.

Operational Risk Indicators

Facility closure announcement (Oct 2025): Closing 5 underperforming facilities; laying off 400 employees. [S5]

• This is a positive signal (pruning bad assets) but also indicates the prior expansion was undisciplined
• Management acknowledged de novo startup losses have been higher than planned

Medicaid dependency and regulatory risk:

• NY Medicaid policy: $25-30M EBITDA headwind in 2026
• Federal Medicaid: DOGE-related federal budget discussions create policy uncertainty
• Pattern: State Medicaid rate changes are the most frequent source of earnings volatility for ACAD

Accounting Quality Flags

Flag	Severity	Notes
Large goodwill ($1.3B, 23% of assets)	Medium	Post-impairment; future impairment risk remains
Negative free cash flow (FY2024-2025)	High	CapEx-driven; expected to reverse 2026; must confirm
Legal charges embedded in OCF	Medium	Obscures true operating cash conversion
Adjusted EBITDA excludes SBC	Low	Standard for sector; $32M SBC is ~5% of Adj. EBITDA
Revenue recognition (ASC 606)	Low	Standard patient service revenue; no concerning flags

3. Financial Quality Summary

Overall Financial Quality: MEDIUM

The underlying revenue and Adj. EBITDA trajectory are solid — $3.3B revenue growing mid-single digits, ~18% Adj. EBITDA margin, strong operational scale. The quality concerns are:

1. Legal/regulatory overhang (DOJ Criminal + SEC) — binary tail risk
2. FCF deeply negative from CapEx cycle; normalization expected in 2026 but not yet demonstrated
3. Balance sheet leverage (4.1x net debt/Adj. EBITDA) limits financial flexibility
4. Management credibility damage from prior guidance misses and legal failings

Source Index

ID	Source
S1	SEC XBRL CIK0001520697; 8-K FY2025 earnings press release
S2	Company 10-K FY2025 (filed 2026-02-27)
S3	Web search: Acadia Healthcare DOJ settlement (bhbusiness.com Sep 2024)
S4	Web search: ACHC securities settlement $179M (bhbusiness.com Nov 2025); jury verdict May 2026
S5	Web search: Acadia Healthcare facility closures, layoffs Oct 2025 (bhbusiness.com)

---

source: coverage-next-full ticker: ACAD company: Acadia Healthcare Company, Inc. step: 12 title: Bull vs. Bear — Analyst Debate created: 2026-05-27

Step 12 — Bull vs. Bear: ACAD

Note: Transcript analysis was not performed on this step — this is the filings-and-consensus path (coverage-next-full). The analyst debate is inferred from consensus notes, press releases, investor commentary, and activist filings.

1. The Core Debate

The fundamental tension in the ACAD investment thesis is:

Bull: Acadia is a deeply discounted pure-play behavioral health operator with a structurally growing TAM, a real (if narrow) moat from CON laws + CTC scale, and a clear FCF inflection as the CapEx cycle moderates. Legal/regulatory overhang is a tail risk that is either already priced in or will resolve in a manageable way. Activist pressure creates M&A optionality at 9-10x EBITDA.

Bear: ACAD is a Medicaid-dependent, leveraged, legally-compromised operator that spent $1.2B on CapEx in two years and has a $1.1B loss to show for it. The DOJ Criminal investigation could result in charges that impair the company's ability to receive Medicaid/Medicare payments. Medicaid policy risk is real and underpriced. Management has repeatedly missed guidance. The CapEx discipline story is unproven.

2. Point/Counterpoint Analysis

Bull Argument	Bear Counter
Structural demand tailwind: 52M mental illness sufferers, opioid crisis, destigmatization	Demand doesn't equal revenue — Medicaid rates constrain monetization; if states cut rates, demand is irrelevant
CapEx cycle ending: FY2026 guide $255-280M vs. $690M peak = 60% reduction	Management missed CapEx guidance in FY2024 (actuals $690M vs. ~$550M guide); FY2026 guidance may prove optimistic
FCF inflection: at $267M CapEx + $600M EBITDA, FCF could be $150M+ in 2026	FCF still suppressed by $100-150M legal payments + $140M interest + taxes; true FCF may be $50-100M even in "good" 2026
Activist M&A optionality: 5.5% Khrom + 3% Engine = credible pressure; PE takeout at 9-10x EBITDA = $30-35/share	M&A processes at levered companies under DOJ investigation are complex; buyers face legal liability; deal may not materialize
Legal resolution pathway: prior OIG/DOJ civil case resolved at $19.85M (modest)	DOJ Criminal Division ≠ civil division; criminal charges could include executives, corporate integrity agreements, or debarment
CTC scale (174 locations, 74K patients/day) is unique, defensible, high-return	CTC revenue depends on federal opioid treatment policy; buprenorphine prescribing expansion (direct primary care) could substitute
Q1 2026 momentum: +7.6% revenue growth, raised guidance	Single quarter does not establish a trend; NY Medicaid headwind will bite in subsequent quarters
Stock at ~8x EV/EBITDA vs. historical 12-15x = 35-50% upside to historical multiple	Historical multiple was earned pre-investigation; the "discount" may be permanent re-rating for legal/governance risk

3. Bull Case — 3 Key Arguments

1. FCF inflection is real and near: The FY2026 CapEx guidance of $255-280M represents a $300M+ reduction from the FY2025 run rate. If management delivers on this, FCF turns meaningfully positive for the first time since FY2023. This is the most important catalyst in the next 12 months and is within management's control (not dependent on market or regulatory factors).

2. DOJ resolution creates re-rating potential: The stock's current discount to historical multiples (~8x vs. 12-15x) is largely attributable to the legal overhang. Resolution — even at a substantial cash settlement — would remove the binary risk that suppresses the multiple. A 9x EBITDA multiple on $600M+ EBITDA = $5.4B EV → ~$30/share at current debt levels. A 10x multiple = $6.0B EV → ~$36/share.

3. Activist pressure creates floor and strategic optionality: With Khrom (5.5%) and Engine (3%) actively engaged, the strategic alternatives process is a real possibility. A behavioral health platform with $3.3B revenue and $600M EBITDA at 9-10x EV/EBITDA would be valued at $5.4-6.0B enterprise value. At $2.5B debt, equity value = $2.9-3.5B = $32-39/share — a 15-40% premium to current price. PE sponsors have historically been active acquirers in behavioral health.

4. Bear Case — 3 Key Arguments

1. DOJ Criminal investigation could be existential: Behavioral health criminal fraud prosecutions have resulted in outcomes ranging from large settlements to exclusion from federal healthcare programs. If Acadia faces a criminal guilty plea with a Corporate Integrity Agreement AND a large settlement ($500M+), the balance sheet (currently $2.5B debt, $133M cash) could be severely strained. Debt/EBITDA could spike above 5x, triggering covenant concerns and refinancing risk.

2. Medicaid structural headwind is systematic: NY is not the last Medicaid adverse event — it's the first of potentially many. With 57.7% of revenue Medicaid-dependent and federal/state budget pressure increasing, rate cuts are more likely than rate increases. Each 1% across-the-board Medicaid rate cut reduces revenue by ~$19M and EBITDA by a similar amount. A 3-5% Medicaid rate shock would wipe out the current FCF inflection thesis entirely.

3. CapEx and execution track record is poor: The same management team (or board) that oversaw $1.13B in incremental debt buildup, $996M goodwill impairment, and repeated CapEx guidance misses is now asking investors to trust a 60% CapEx reduction. The 5 facility closures and 400 layoffs represent capital destruction from the prior growth cycle. If de novo ramp-up costs continue to exceed guidance or if additional facility closures are required, the thesis unravels.

Source Index

ID	Source
S1	Web search: activist investor analysis, Khrom Capital, Engine Capital (funanc1al.com, ts2.tech)
S2	Web search: ACHC analyst debate, guidance history (markets.financialcontent.com)
S3	Company Q1 2026 results; FY2026 guidance (sec.gov 8-K)
S4	Web search: DOJ Criminal behavioral health enforcement precedents